Yuan Zixu, Baker Kelsey, Redman Mary W, Wang Lei, Adams Scott V, Yu Ming, Dickinson Brandon, Makar Karen, Ulrich Neli, Böhm Jürgen, Wurscher Michelle, Westerhoff Maria, Medwell Steve, Moonka Ravi, Sinanan Mika, Fichera Alessandro, Vickers Kathy, Grady William M
Department of Colorectal Surgery, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510655, China.
Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510655, China.
Br J Cancer. 2017 Oct 10;117(8):1202-1210. doi: 10.1038/bjc.2017.266. Epub 2017 Aug 15.
Plasma microRNAs (miRNAs) are promising non-invasive biomarkers for colorectal cancer (CRC) prognosis. However, the published studies to date have yielded conflicting and inconsistent results for specific plasma miRNAs.
We have conducted a study using robust assays to assess a panel of nine miRNAs for CRC prognosis and early detection of recurrence. Plasma samples from 144 patients in a prospective CRC cohort study were collected at diagnosis, 6, 12, and 24 months after diagnosis. miRNAs were assayed by Taqman qRT-PCR to generate miRNA normalised copy numbers.
Preoperative high plasma miRNA levels were associated with increased recurrence risk for miR-200b (HR [95% CI]=2.04 [1.00, 4.16], P=0.05), miR-203 (HR=4.2 [1.48, 11.93], P=0.007), miR-29a (HR=2.61 [1.34,5.07], P=0.005), and miR-31 (HR=4.03 [1.76, 9.24], P=0.001). Both plasma miR-31 (AUC: 0.717) and miR-29a (AUC: 0.703) could discriminate recurrence from these patients without recurrence. In addition, high levels of miR-31 during surveillance was associated with a three-fold increased risk of recurrence across all time points. Dynamic postoperative plasma miR-141 and 16 levels correlated with recurrence in the surveillance samples.
Pre-operative plasma miR-29a, 200b, 203, and 31 are potential CRC prognosis biomarkers. In addition, dynamic postoperative miR-31, 141 and 16 levels are potential biomarkers for the early detection of recurrence during CRC surveillance.
血浆微小RNA(miRNA)是用于结直肠癌(CRC)预后的有前景的非侵入性生物标志物。然而,迄今为止已发表的研究针对特定血浆miRNA得出了相互矛盾且不一致的结果。
我们开展了一项研究,使用可靠的检测方法评估一组9种miRNA用于CRC预后及复发的早期检测。在前瞻性CRC队列研究中,收集了144例患者在诊断时、诊断后6、12和24个月的血浆样本。通过Taqman qRT-PCR检测miRNA以生成miRNA标准化拷贝数。
术前血浆miRNA高水平与miR-200b(风险比[95%置信区间]=2.04[1.00, 4.16],P=0.05)、miR-203(风险比=4.2[1.48, 11.93],P=0.007)、miR-29a(风险比=2.61[1.34, 5.07],P=0.005)和miR-31(风险比=4.03[1.76, 9.24],P=0.001)的复发风险增加相关。血浆miR-31(曲线下面积:0.717)和miR-29a(曲线下面积:0.703)均可区分这些复发患者和未复发患者。此外,监测期间miR-31高水平与所有时间点复发风险增加三倍相关。术后动态血浆miR-141和16水平与监测样本中的复发相关。
术前血浆miR-29a、200b、203和31是潜在的CRC预后生物标志物。此外,术后动态miR-31、141和16水平是CRC监测期间复发早期检测的潜在生物标志物。